Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02840552
Other study ID # 16-061
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 2016
Est. completion date March 2018

Study information

Verified date August 2018
Source Sir Mortimer B. Davis - Jewish General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objectives of this study are to confirm the safety and efficacy of FCH-PET/CT and to establish our ability to reproduce results from the literature using FCH-PET/CT as a diagnostic and decision making tool in the management in two predefined groups of prostate cancer patients, specifically, biochemical recurrence and high risk staging. The primary endpoints of the study are the incidence of adverse events (AE) in the study population up to 24 hours following the scan, and the sensitivity and specificity of FCH-PET/CT vs CT on a per-patient and per-lesion basis.


Description:

Background Prostate cancer is the second leading cause of cancer death in North American men older than 50 years. Positron emission tomography / computer tomography (PET/CT) is a nuclear medicine procedure based on the measurement of positron emission from radiolabeled tracer molecules. A common radiotracer in use today is 18F-fluoromethylcholine (aka fluorocholine or FCH) which is a radiolabeled choline derivative. Imaging with FCH-PET/CT can be used to characterize and localize prostate cancer in vivo. There is extensive data in the literature showing the value of FCH-PET/CT imaging in accurately staging and restaging prostate cancer. FCH-PET/CT is standard of care in many European countries.

Study Objectives The objectives of this study are to confirm the safety and efficacy of FCH-PET/CT and to establish our ability to reproduce results from the literature using FCH-PET/CT as a diagnostic and decision making tool in the management in two predefined groups of prostate cancer patients, specifically, biochemical recurrence and high risk staging. The primary endpoints of the study are the incidence of adverse events (AE) in the study population up to 24 hours following the scan, and the sensitivity and specificity of FCH-PET/CT vs CT on a per-patient and per-lesion basis.

Study Design This will be a multi-center open label study in which one (1) FCH-PET/CT will be performed on study participants. A PET/CT scan takes 2-3 hours.

Safety FCH-PET/CT exhibits favorable dosimetry, delivering organ doses that are comparable to or lower than those delivered by 18F-FDG. The safety of FCH is not disputed and we expect the number of adverse events in our study to be zero.

Sample Size and Recruitment Target enrollment is 1500 patients. This will be sufficient to detect AE with a prevalence of 0.3% with 99% confidence. For efficacy endpoints, approximately 500 subjects would provide 90% power at the alpha=0.05 one-sided level of significance that the specificity and sensitivity will be superior to the specificity and sensitivity under the null hypothesis. Patients will be recruited by urologists in the clinical setting. Initial contact and consent will be by the department of urology.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date March 2018
Est. primary completion date February 2018
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 120 Years
Eligibility Global Inclusion Criteria:

- Resident of Canada

- Male sex

- Age 18 years or older

- Previously diagnosed with prostate cancer, under referring physician's care

- ECOG performance status 0 - 3, inclusive

- Able to understand and provide written informed consent

- Able to tolerate the physical/logistical requirements of completing a PET/CT scan including lying supine (or prone) for up to 40 minutes and tolerating intravenous cannulation for injection

Global Exclusion Criteria:

- Patients who are medically unstable (e.g. acute cardiac or respiratory distress or hypotensive)

- Patients who exceed the safe weight limit of the PET/CT bed (usually approximately 400 lbs.) or who cannot fit through the PET/CT bore (usually approximately 70 cm diameter)

- Patients who are claustrophobic.

Clinical Indication Criteria Subgroups:

- BCR: Biochemical recurrence as defined by serum PSA > 1 ng/ml following either radical prostatectomy or curative-intent radiotherapy or other prostate-ablative definitive management.

- HRS: Staging of high risk patients as defined by any one of the following:

- Gleason score > 7

- Serum PSA > 15 ng/ml

- T stage of T3 or greater on TNM staging

- Equivocal conventional staging such as CT, MRI or bone scan

- Clinical suspicion of advance stage disease (e.g. bone pain)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
18F-Fluoromethylcholine (18F-FCH)
FCH PET/CT

Locations

Country Name City State
Canada Jewish General Hospital Montreal Quebec

Sponsors (1)

Lead Sponsor Collaborator
Sir Mortimer B. Davis - Jewish General Hospital

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of FCH-PET/CT imaging as measured by the incidence of adverse events (AE) 7 days
Primary Efficacy of FCH-PET/CT imaging as measured by sensitivity and specificity vs CT on a per patient basis as compared to standard of truth 12 months
Primary Efficacy of FCH-PET/CT imaging as measured by sensitivity and specificity vs CT on a per lesion basis as compared to standard of truth 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A